Repurposing SGLT2 inhibitors for autoimmune diseases? YES, WE MAY!

Michelangelo Certo; Jennifer Niven; Claudio Mauro

doi:10.1016/j.chembiol.2023.07.020

Repurposing SGLT2 inhibitors for autoimmune diseases? YES, WE MAY!

Michelangelo Certo, Jennifer Niven, Claudio Mauro

Inflammation and Ageing

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

T cells play a key role in driving autoimmunity, with alterations in metabolism powering their effector function. In the July 11 issue of Cell Metabolism, Jenkins et al. 1 describe how a type 2 diabetes drug, canagliflozin, can be repurposed for the treatment of autoimmune disorders through metabolic reprogramming of the T cell response.

Original language	English
Pages (from-to)	1009-1011
Number of pages	3
Journal	Cell Chemical Biology
Volume	30
Issue number	9
DOIs	https://doi.org/10.1016/j.chembiol.2023.07.020
Publication status	Published - 21 Sept 2023

Bibliographical note

Keywords

Humans
Sodium-Glucose Transporter 2 Inhibitors/pharmacology
Diabetes Mellitus, Type 2/drug therapy
Drug Repositioning
Autoimmune Diseases/drug therapy
Canagliflozin/pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.chembiol.2023.07.020

Cite this

@article{ce1196d72a544b7ea7f8441fd5f12f2d,

title = "Repurposing SGLT2 inhibitors for autoimmune diseases? YES, WE MAY!",

abstract = "T cells play a key role in driving autoimmunity, with alterations in metabolism powering their effector function. In the July 11 issue of Cell Metabolism, Jenkins et al. 1 describe how a type 2 diabetes drug, canagliflozin, can be repurposed for the treatment of autoimmune disorders through metabolic reprogramming of the T cell response. ",

keywords = "Humans, Sodium-Glucose Transporter 2 Inhibitors/pharmacology, Diabetes Mellitus, Type 2/drug therapy, Drug Repositioning, Autoimmune Diseases/drug therapy, Canagliflozin/pharmacology",

author = "Michelangelo Certo and Jennifer Niven and Claudio Mauro",

year = "2023",

month = sep,

day = "21",

doi = "10.1016/j.chembiol.2023.07.020",

language = "English",

volume = "30",

pages = "1009--1011",

journal = "Cell Chemical Biology",

issn = "2451-9448",

publisher = "Elsevier",

number = "9",

}

TY - JOUR

T1 - Repurposing SGLT2 inhibitors for autoimmune diseases? YES, WE MAY!

AU - Certo, Michelangelo

AU - Niven, Jennifer

AU - Mauro, Claudio

PY - 2023/9/21

Y1 - 2023/9/21

N2 - T cells play a key role in driving autoimmunity, with alterations in metabolism powering their effector function. In the July 11 issue of Cell Metabolism, Jenkins et al. 1 describe how a type 2 diabetes drug, canagliflozin, can be repurposed for the treatment of autoimmune disorders through metabolic reprogramming of the T cell response.

AB - T cells play a key role in driving autoimmunity, with alterations in metabolism powering their effector function. In the July 11 issue of Cell Metabolism, Jenkins et al. 1 describe how a type 2 diabetes drug, canagliflozin, can be repurposed for the treatment of autoimmune disorders through metabolic reprogramming of the T cell response.

KW - Humans

KW - Sodium-Glucose Transporter 2 Inhibitors/pharmacology

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Drug Repositioning

KW - Autoimmune Diseases/drug therapy

KW - Canagliflozin/pharmacology

U2 - 10.1016/j.chembiol.2023.07.020

DO - 10.1016/j.chembiol.2023.07.020

M3 - Comment/debate

C2 - 37738952

SN - 2451-9448

VL - 30

SP - 1009

EP - 1011

JO - Cell Chemical Biology

JF - Cell Chemical Biology

IS - 9

ER -

Repurposing SGLT2 inhibitors for autoimmune diseases? YES, WE MAY!

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this